ReviewClinical and translational science2025
Novel Kidney Biomarkers and Antibiotics-Induced Acute Kidney Injury: A Practical Assessment of Current and Future Applications.
Review in Clinical and translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hesperidin attenuates gentamicin-induced nephrotoxicity: Association with SIRT3 and PAX2 expression, oxidative stress, and tubular injury.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Novel Kidney Biomarkers and Antibiotics-Induced Acute Kidney Injury: A Practical Assessment of Current and Future Applications.Clinical and translational science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several antibiotics have nephrotoxic potential and an undeniable role in the development of acute kidney injury (AKI). The current AKI definition and operational criteria are dependent on functional biomarkers, serum creatinine and urine output, to identify and quantify kidney dysfunction and injury. However, there is a tremendous amount of research on novel kidney biomarkers that can be used in the assessment (i.e., prediction, detection, and prognosis) of AKI. This narrative review aimed to discuss different aspects of using novel kidney biomarkers in the context of AKI caused by selected anti-infectives including vancomycin, aminoglycosides, amphotericin B, and polymyxins as examples. Clinical studies on biomarker utilization have focused on diagnosis and detection. Urinary tissue inhibitor of metalloproteinases-2/insulin-like growth factor-binding protein-7, urine/plasma neutrophil gelatinase-associated lipocalin, and serum cystatin C are prominent novel kidney biomarkers studied in the milieu of anti-infective-induced AKI. Several practical issues should be considered in the application of novel kidney biomarkers in the context of antibiotic-induced AKI including: (1) the potential impact of non-kidney factors on biomarker results, (2) the utility of an optimal panel of biomarkers, (3) the appropriate starting time, frequency, and time intervals of urine/plasma sampling, (4) having a standard approach for urine sampling (random spot vs. 24-h or serial measurements), (5) ascertainment of clinically significant and diagnostic threshold values/concentrations for each biomarker, and (6) consideration of cost issues for routine use in clinical practice. Overall, novel kidney biomarkers have the potential to improve prediction and detection of antibiotic-induced AKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.